Emalex ,Lusaris, Novadip Biosciences
Novadip Biosciences Raises Additional EUR 40M in Series B Funding
Novadip Biosciences, a Mont Saint-Guibert, Belgium-based clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, raised an additional EUR 40m in a Series B equity round and non-dilutive funding.
The EUR 40m financing is comprised of EUR 24m in new equity and EUR 16m in non-dilutive financing mainly by the Walloon Region. CR-CP Life Science Fund (China) joined existing investors, including New Science Ventures (US), Fund+, SRIW Life Sciences, VIVES Louvain Technology Fund, InvestSud, family offices and private investors, such as Pierre Drion and Olivier van der Rest, to support the equity round.
Co-Founded in 2013 by Denis Dufrane, MD, PhD, CEO, Novadip Biosciences is a clinical stage company developing best in class tissue regeneration therapies to elevate the standard of care for critical size bone defects, common orthopedic conditions, and cancer.
Novadip Biosciences Raises Additional EUR 40M in Series B Funding
Novadip Biosciences, a Mont Saint-Guibert, Belgium-based clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, raised an additional EUR 40m in a Series B equity round and non-dilutive funding
Emalex Biosciences Raises $250M in Series D Financing Round
Emalex Biosciences, a Chicago, IL-based biotechnology company, raised $250M in Series D funding.
The round was led by Bain Capital Life Sciences with participation from Paragon Biosciences, Valor Equity Partners, and Fidelity Management & Research Company, and several family offices.
The company intends to use the capital to fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome.
Founded by Jeff Aronin, Emalex Biosciences was created by Paragon Biosciences to develop treatments for central nervous system disorders.
The Phase 3 clinical trial for its investigational first-in-class new drug ecopipam, a novel dopamine-1 receptor antagonist, is expected to enroll more than 220 patients across approximately 90 sites.
Emalex Biosciences Raises $250M in Series D Financing Round
Emalex Biosciences, a Chicago, IL-based biotechnology company , raised $250M in Series D funding
Lusaris Therapeutics Launches with $60M Series A Financing
Lusaris Therapeutics, a Boston, MA-based biotechnology company, raised $60M in Series A financing.
The round was led by RA Capital Management, with participation from Venrock Healthcare Capital Partners, Deep Track Capital, and Boxer Capital.
The company intends to use the funds to further develop its health solutions, expand operations and its business reach.
Led by CEO Andrew Levin and Chief Operating Officer Neil Buckley, Lusaris Therapeutics is a biotechnology company advancing serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company’s pipeline includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions including migraine and cluster headache.
Lusaris is also announcing it has entered into a strategic collaboration with Catalent under which Lusaris has been granted an exclusive worldwide license to Catalent’s Zydis fast-dissolving tablet technology for the 5-MeO-DMT program.
Lusaris Therapeutics Launches with $60M Series A Financing
Lusaris Therapeutics, a Boston, MA-based biotechnology company, raised $60M in Series A financing
Werfen to Acquire Immucor, for approx. USD2 Billion
Werfen, a Barcelona, Spain-based manufacturer and distributor of Specialized Diagnostic instruments, related reagents, automation workcells, and data management solutions, acquired Immucor, a Norcross, Georgia, USA-based transfusion and transplant in vitro diagnostics company, from TPG.
The amount of the deal – expected to close during the first half of 2023 – is expected to be approximately US$2 billion. The acquisition will allow Werfen to expand its portfolio of Specialized Diagnostics solutions for hospitals and clinical laboratories. Upon completion of this acquisition, and based on 2021 figures, Werfen will surpass €2.2 billion in revenue, with seven technology centers, close to 7,000 employees worldwide, and a direct presence in 30 countries and more than 100 territories through distributors.
Led by Avi Pelossof, CEO, Immucor is a provider of transfusion and transplantation diagnostic products worldwide.
Led by CEO Carlos Pascual, Werfen is a developer, manufacturer and distributor of Specialized Diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. Its business units include Hemostasis, Acute Care Diagnostics, Autoimmunity, and Original Equipment Manufacturing (OEM).
